• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Precigen Announces Up to $125 Million Non-Dilutive Financing

    9/3/25 7:00:00 AM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PGEN alert in real time by email

    $100 million funded at close fortifies balance sheet and supports robust US commercialization of PAPZIMEOS, as well as potential expansion into international markets and the pursuit of pediatric and other HPV-related indications

    GERMANTOWN, Md., Sept. 2, 2025 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced that it has entered into a credit facility agreement with investment funds managed by Pharmakon Advisors, LP.

    Precigen Logo (PRNewsfoto/Precigen, Inc.)

    "I am pleased to announce this non-dilutive financing with Pharmakon, a respected leader in strategic life sciences funding," said Helen Sabzevari, PhD, President and CEO of Precigen. "This fortifies our position for robust US commercialization of PAPZIMEOS, our groundbreaking novel immunotherapy, while also supporting efforts to expand to international markets and pursue pediatric and additional HPV-related indications. Precigen has demonstrated the strength of our innovative therapeutic platforms and is now advancing into the next stage as a commercial company. With the potential for revenue from PAPZIMEOS on the horizon, we are well-positioned to deliver meaningful growth and establish Precigen as a leading biopharma innovator."

    Harry Thomasian, Jr., Chief Financial Officer of Precigen adds, "Strengthening our balance sheet provides us with the financial flexibility to commercialize PAPZIMEOS while advancing our broader strategic objectives as Precigen enters a period of projected significant growth."

    The credit facility provides Precigen with up to $125 million committed across two tranches, subject to the terms and conditions of the agreement:

    • The first tranche of $100 million was funded at closing.
    • A second tranche of $25 million can be drawn at Precigen's discretion through March 31, 2027, subject to certain conditions.

    The credit facility will mature on the fifth anniversary of the closing date of the first tranche. The credit facility bears interest at a variable rate per year equal to 6.50% plus three-month secured overnight financing rate (SOFR) with a SOFR floor of 3.75%. The credit facility can be prepaid in whole at Precigen's discretion at any time, subject to prepayment fees. Additional information on the agreement is filed as a Current Report on Form 8-K.

    Evercore served as financial advisor and Davis Polk LLP served as legal advisor to Precigen. Akin served as legal advisor to Pharmakon Advisors, LP.

    Pharmakon Advisors, LP is a leading investor in non-dilutive debt for the life sciences industry and is the investment manager of the BioPharma Credit funds. Established in 2009, funds managed by Pharmakon Advisors, LP have committed over $10 billion across 59 investments.

    Precigen: Advancing Medicine with Precision®

    Precigen (NASDAQ:PGEN) is a biopharmaceutical company specializing in the advancement of innovative precision medicines to address difficult-to-treat diseases with high unmet patient need. Precigen is dedicated to advancing scientific breakthroughs from proof-of-concept through commercialization. With a strong commitment to innovation, Precigen is developing a robust pipeline of differentiated therapies across its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. For more information about Precigen, visit www.precigen.com or follow us on LinkedIn or YouTube.

    Trademarks

    Precigen, PAPZIMEOS, AdenoVerse, and Advancing Medicine with Precision are trademarks of Precigen and/or its affiliates. Other names may be trademarks of their respective owners.

    Cautionary Statement Regarding Forward-Looking Statements

    This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what the Company expects. Examples of forward-looking statements include, among others, information relating to the Company's business and business plans, the success of efforts to commercialize PAPZIMEOS™ (zopapogene imadenovec-drba) for the treatment of recurrent respiratory papillomatosis (RRP) in adults, the Company's ability to successfully obtain foreign regulatory approvals for PAPZIMEOS, expectations about the safety and efficacy of PAPZIMEOS and the Company's other product candidates, the timing of clinical trials and their results, the Company's ability to commence clinical studies or complete ongoing clinical studies, and the ability of PAPZIMEOS to treat RRP. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For further information on potential risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in the Company's most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission.

    Investor Contact:

    Steven M. Harasym

    Tel: +1 (202) 365-2563

    [email protected]

    Media Contact:

    Donelle M. Gregory

    [email protected]

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/precigen-announces-up-to-125-million-non-dilutive-financing-302544623.html

    SOURCE Precigen, Inc.

    Get the next $PGEN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PGEN

    DatePrice TargetRatingAnalyst
    8/15/2025Underweight → Neutral
    Analyst
    3/22/2024Neutral → Underweight
    JP Morgan
    5/23/2023Neutral
    JP Morgan
    11/18/2022$7.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $PGEN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Precigen Announces Up to $125 Million Non-Dilutive Financing

    $100 million funded at close fortifies balance sheet and supports robust US commercialization of PAPZIMEOS, as well as potential expansion into international markets and the pursuit of pediatric and other HPV-related indications GERMANTOWN, Md., Sept. 2, 2025 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced that it has entered into a credit facility agreement with investment funds managed by Pharmakon Advisors, LP. "I am pleased to announ

    9/3/25 7:00:00 AM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Precigen to Participate in Upcoming Virtual Fireside Chats Hosted by Cantor and H.C. Wainwright

    GERMANTOWN, Md., Aug. 25, 2025 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced that Precigen will participate in two upcoming virtual fireside chats hosted by Jennifer Kim of Cantor, and Swayampakula Ramakanth, PhD, of H.C. Wainwright to discuss the recent approval of the first and only FDA-approved therapy for the treatment of adults with recurrent respiratory papillomatosis. Cantor Virtual Fireside ChatAugust 27, 2025, 11 AM – 12 PM ET

    8/25/25 8:05:00 AM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis

    PAPZIMEOS approval marks a historic milestone for the RRP patient community as the first and only FDA-approved therapy for the treatment of adults with RRP PAPZIMEOS received full approval from the FDA for the treatment of adults with RRP; a confirmatory clinical trial is no longer required RRP is a rare, debilitating, and potentially life-threatening disease caused by chronic HPV 6 or HPV 11 infection, which results in recurrent benign tumors in the respiratory tract; RRP affects an estimated 27,000 adult patients in the USPAPZIMEOS is a non-replicating adenoviral vector-based immunotherapy designed to generate an immune response directed against papilloma cells expressing HPV 6/11—the firs

    8/15/25 7:00:00 AM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PGEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Precigen upgraded by Analyst

    Analyst upgraded Precigen from Underweight to Neutral

    8/15/25 8:13:17 AM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Precigen downgraded by JP Morgan

    JP Morgan downgraded Precigen from Neutral to Underweight

    3/22/24 7:52:12 AM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    JP Morgan initiated coverage on Precigen

    JP Morgan initiated coverage of Precigen with a rating of Neutral

    5/23/23 7:32:58 AM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PGEN
    SEC Filings

    View All

    Precigen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - PRECIGEN, INC. (0001356090) (Filer)

    9/3/25 7:05:52 AM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3 filed by Precigen Inc.

    S-3 - PRECIGEN, INC. (0001356090) (Filer)

    8/19/25 5:31:36 PM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Precigen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - PRECIGEN, INC. (0001356090) (Filer)

    8/18/25 5:06:56 PM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PGEN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Agee Nancy H bought $69,000 worth of shares (15,000 units at $4.60), increasing direct ownership by 7% to 217,841 units (SEC Form 4)

    4 - PRECIGEN, INC. (0001356090) (Issuer)

    9/5/25 5:46:22 PM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Agee Nancy H bought $98,643 worth of shares (26,005 units at $3.79), increasing direct ownership by 15% to 202,841 units (SEC Form 4)

    4 - PRECIGEN, INC. (0001356090) (Issuer)

    8/29/25 4:21:18 PM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, IP Affairs Perez Jeffrey Thomas bought $50,000 worth of shares (58,823 units at $0.85), increasing direct ownership by 9% to 743,097 units (SEC Form 4)

    4 - PRECIGEN, INC. (0001356090) (Issuer)

    8/13/24 5:09:47 PM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PGEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Agee Nancy H bought $69,000 worth of shares (15,000 units at $4.60), increasing direct ownership by 7% to 217,841 units (SEC Form 4)

    4 - PRECIGEN, INC. (0001356090) (Issuer)

    9/5/25 5:46:22 PM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Agee Nancy H bought $98,643 worth of shares (26,005 units at $3.79), increasing direct ownership by 15% to 202,841 units (SEC Form 4)

    4 - PRECIGEN, INC. (0001356090) (Issuer)

    8/29/25 4:21:18 PM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Agee Nancy H converted options into 126,760 shares, increasing direct ownership by 253% to 176,836 units (SEC Form 4)

    4 - PRECIGEN, INC. (0001356090) (Issuer)

    7/7/25 4:26:36 PM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PGEN
    Leadership Updates

    Live Leadership Updates

    View All

    Precigen Reports First Quarter 2025 Financial Results and Business Updates

    PRGN-2012 has the potential to be the first- and best-in-class treatment for RRPCompany's BLA for PRGN-2012 for the treatment of adults with RRP is under priority review by the FDA with a PDUFA target action date set for August 27, 2025RRP is a rare, debilitating chronic disease with approximately 27,000 adult patients in the US and more than 125,000 patients outside of the USCompany continues to rapidly advance commercial and manufacturing readiness campaign in anticipation of 2025 commercial launch Company and Recurrent Respiratory Papillomatosis Foundation to host the 2025 International RRP Awareness Day on June 11Cash, cash equivalents, and investments of $81.0 million as of March 31, 20

    5/14/25 4:05:00 PM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Precigen and Recurrent Respiratory Papillomatosis Foundation to Host the 2025 International RRP Awareness Day on June 11th

    – International event will raise awareness and bring together RRP patients, caregivers, and the healthcare community supporting them –– Recurrent respiratory papillomatosis is a rare, debilitating, chronic disease that impacts both children and adults and is mainly driven by HPV 6/11 infection –– There is no FDA-approved therapeutic for the treatment of RRP, and the current standard-of-care is repeated surgeries, which do not address the underlying cause of disease and are associated with significant morbidity and risk of irreversible injury – GERMANTOWN, Md., April 16, 2025 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovativ

    4/16/25 8:05:00 AM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Precigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy Launch

    –  Company strengthens focus on building and optimizing commercial readiness and pre-launch activities for PRGN-2012 in recurrent respiratory papillomatosis – GERMANTOWN, Md., July 23, 2024 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the appointment of Phil Tennant as the Company's chief commercial officer. Mr. Tennant will be responsible for commercial strategy and execution across US and global markets. His initial focus will be on driving commercial readiness activities for the potential launch of the first- and best-in-class PRGN-2012 Aden

    7/23/24 8:01:00 AM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PGEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Precigen Inc.

    SC 13D/A - PRECIGEN, INC. (0001356090) (Subject)

    8/13/24 4:05:10 PM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Precigen Inc. (Amendment)

    SC 13D/A - PRECIGEN, INC. (0001356090) (Subject)

    5/3/24 8:01:15 PM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Precigen Inc. (Amendment)

    SC 13G/A - PRECIGEN, INC. (0001356090) (Subject)

    2/27/24 1:48:40 PM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PGEN
    Financials

    Live finance-specific insights

    View All

    Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis

    PAPZIMEOS approval marks a historic milestone for the RRP patient community as the first and only FDA-approved therapy for the treatment of adults with RRP PAPZIMEOS received full approval from the FDA for the treatment of adults with RRP; a confirmatory clinical trial is no longer required RRP is a rare, debilitating, and potentially life-threatening disease caused by chronic HPV 6 or HPV 11 infection, which results in recurrent benign tumors in the respiratory tract; RRP affects an estimated 27,000 adult patients in the USPAPZIMEOS is a non-replicating adenoviral vector-based immunotherapy designed to generate an immune response directed against papilloma cells expressing HPV 6/11—the firs

    8/15/25 7:00:00 AM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Precigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19th

    GERMANTOWN, Md., March 13, 2025 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the Company will release full year 2024 financial results and provide business updates on Wednesday, March 19, 2025. The Company will host a conference call to discuss results that day at 4:30 PM ET. The conference call may be accessed by dialing 1-800-836-8184 (North America) or 1-646-357-8785 (International). Participants are asked to dial in 10-15 minu

    3/13/25 8:05:00 AM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Precigen Announces $79.0 Million Private Placement Offering of Convertible Preferred Stock

    GERMANTOWN, Md., Dec. 27, 2024 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that it has entered into a securities purchase agreement for the sale of its 8.00% Series A Convertible Perpetual Preferred Stock (Preferred Stock) in a private placement. Precigen anticipates gross proceeds from the private placement of $79.0 million before deducting offering expenses. In addition, the investors will have rights to exercise warrants to purchase 52,666,669 shares of Precigen's common stock at an exercise price of $0.75 per share (Warrants). The offering

    12/27/24 9:00:00 AM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care